

---

---

## *References*

---

---

## REFERENCES

- Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, Langer K. 2005. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. *Biomaterials* 26 (15):2723-2732.
- Begley DJ. 2003. Understanding and circumventing the blood-brain barrier. *Acta Paediatr Suppl* 443:83-91.
- Boado RJ. 2005. RNA interference and nonviral targeted gene therapy of experimental brain cancer. *Neuro Rx* 2:139-150.
- Browne TR, Holmes GL. *Epilepsy* 2001. *New Engl J Med* 344:1145-1151.
- Burstein AH, Cox DS, Mistry B, Eddington ND 1999. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. *Epilepsy Res* 34:129-133.
- Cassano R, Trombino S, Ferrarelli T, Cavalcanti P, Giraldi C, Lai F, Loy G, Picci N. 2012. Synthesis, characterization and in-vitro antitubercular activity of isoniazid-gelatin conjugate. *J Pharm Pharmacol* 64(5):712-718.
- Celia C, Cosco D, Paolino D, Fresta M. 2010. Nanoparticulate devices for brain drug delivery. *Med Res Rev* 31:716-756.
- Chang G. 2003. Multidrug resistance ABC transporters. *FEBS Lett* 555:102-105.

- Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. 1990. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. *J Biol Chem* 265:10073-10080.
- Coester CJ, Langer K, von Briesen H, Kreuter J. 2000. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. *J Microencapsul* 17(2):187-193.
- Cole SPC, Bhardway G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* 258:1650-1654.
- Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge, WM. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. *Pharm Res* 17:266-274.
- Copeland JRM, Dewey ME, Wood N, Searle R, Davidson IA, William, MC. 1987. Range of mental illness among the elderly in the community. *Br J Psychiatry* 150:815-823.
- Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci USA* 86:695-698.
- Costa P, Sousa Lobo JM. 2001. Modeling and comparison of dissolution profiles. *Eur J Pharm Sci* 13(2):123-133.

- Dean M, Rzhetsky A, Allikmets R. 2001. The human ATP binding cassette (ABC) transporter superfamily. *Genome Res* 11:1156-1166.
- Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Singh CJS, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. *J Pharmacol Exp Ther* 303:1029-1037.
- Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CECA, Kasman IN, LaPerle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Deussen JWV, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/B knockout mouse model. *Drug Metab Dispos* 33:165-174.
- Elnakat H, Ratnam M. 2004. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. *Adv Drug Deliv Rev* 56(8):1067-1084.
- Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. 2005. Global prevalence of dementia: a Delphi consensus study. *Lancet* 366:2112-2117.

- Garrigues A, Escargueil AE, Orlowski S. 2002. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. *Proc Natl Acad Sci USA* 99:10347-10352.
- Godman & Gilman's 2006. *The pharmacological basis of therapeutics*. Eleventh edition, 501-525.
- Goswamia S, BajpaiaJ, Bajpai AK. 2009. Designing gelatin nanocarriers as a swellable system for controlled release of insulin: An in-vitro kinetic study. *J Macromol Sci, Part A: Pure Appl Chem* 47(2):119-130.
- Griffiths NM, Hirst BH, Simmons NC. 1994. Active intestinal secretion of the fluoroquinolone antibacterial ciprofloxacin, norfloxacin and pefloxacin, a common secretory pathway? *J Pharmacol Exp Ther* 269:496-502.
- Hasebe N, Abe K, Sugiyama E, Hosoi R, Inoue O. 2010. Anticonvulsant effects of methyl ethyl ketone and diethyl ketone in several types of mouse seizure models. *Eur J Pharmacol* 642(1-3):66-71.
- Hirohashi T, Terasaki T, Shigetoshi M, Sugiyama Y. 1997. In vivo and in vitro evidence for non-restricted transport of 2'-bis(2-carboxy-ethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier. *J Pharmacol Exp Ther* 280:813-819.
- Jeffrey P, Summerfield S. 2010. Assessment of the blood-brain barrier in CNS drug discovery. *Neurobiol Dis* 37:33-37.

- Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta* 455:152-162.
- Kaur IP, Bhandari R, Bhandari S, Kakkar V. 2008. Potential of solid lipid nanoparticles in brain targeting. *J Control Release* 127:97-109.
- Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen JP. 1999. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. *Pharm Res* 16:1514-1519.
- Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates?. *Nat Rev Drug Discov* 3:711-715.
- Kusuhara H, Sugiyama Y. 2004. Efflux transport systems for organic anions and cations at the blood-CSF barrier. *Adv Drug Deliv Rev* 56:1741-1763.
- Levitan H, Ziylan Z, Smith QR, Takasato Y, Rapoport SI. 1984. Brain uptake of a food dye, erythrosin B, prevented by plasma protein binding. *Brain Res* 322:131-134.
- Lewis DFV, Dickins M. 2002. Substrate SARs in human P450s. *Drug Discov Today* 7:918-925.
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 23:3-25.

- Lolin YI, Ratnaraj N, Hjelm M, Patsalos PN. 1994. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: Phenytoin. *Epilepsy Res* 19:99-110.
- Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr. 2005. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. *J Med Chem* 48 (19):5892-5899.
- Miller DD, Lenhart W, Antalek BJ, Williams AJ, Hewitt JM. 1994. The use of NMR to study sodium dodecyl sulfate-gelatin interactions. *Langmuir* 10(1):68-71.
- Nakajima N, Ikada Y. 1995. Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media. *Bioconjug Chem* 6(1):123-130.
- Neerati P, Ganji D, Bedada SK 2011. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. *Eur J Pharm Sci* 44 (1-2):27-31.
- Ofokansi K, Winter G, Fricker G, Coester C. 2010. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. *Eur J Pharma Biopharm* 76(1):1-9.
- Ohtsuki S, Terasaki T. 2007. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. *Pharm Res* 24:1745-1758.

- Pardridge WM, Oldendorf WH, Cancilla P, Frank HJ. 1986. Blood-brain barrier: interface between internal medicine and the brain. *Ann Intern Med* 105:82-95.
- Pardridge WM. 2001. Crossing the blood-brain barrier: are we getting it right?. *Drug Discov Today* 6:1-2.
- Pardridge WM. 2002. William Pardridge discusses the lack of BBB research. Interviewed by Rebecca N. Lawrence. *Drug Discov Today* 7:223-226.
- Pardridge WM. 2002b. Drug and gene delivery to the brain: The vascular route. *Neuron* 36:555-558.
- Pardridge WM. 2007. Drug targeting to the brain. *Pharm Res* 24:1733-1744.
- Peterson SL, Albertson TE. 1998. *Neuropharmacology methods in epilepsy research*. USA: CRC Press.
- Polt R, Dhanasekaran M, Keyari CM. 2005. Glycosylated neuropeptides: a new vista for neuropsychopharmacology? *Med Res Rev* 25:557-585.
- Pu YJ, Vaid RK, Boini SK, Towsley RW, Doecke CW, Mitchell D. 2009. A practical method for functionalized peptide or amide bond formation in aqueous-ethanol media with EDC as activator. *Org Process Res. & Dev* 13(2):310-314.
- Punitha AD and Srivastava AK 2013. CNS drug targeting: have we travelled in right path?, *J Drug Target* 21(9):787-800.



- Qazvini NT, Zinatloo S. 2011. Synthesis and characterization of gelatin nanoparticles using CDI/NHS as a non-toxic cross-linking system. *J Mater Sci Mater Med* 22 (1):63-69.
- Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Worms DP. 1999. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. *Proc Natl Acad Sci USA* 96: 3900-3905.
- Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. 2003. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. *Proc Natl Acad Sci USA* 100:9244-9249.
- Robinson JD, Morris BA, Aherne GW. 1975. Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay. *Br J Clin Pharmacol* 2:345-349.
- Roohullah, Iqbal Z, Nasir F, Akhlaq M, Sadozai SK, Khadra I, Zakir S. 2012. Preparation and in-vitro evaluation of sustained release phenytoin sodium matrix tablets prepared by co-evaporation method using different polymers. *Middle-East J of Sci Res* 11(2):246-252.
- Saha TK, Ichikawa H, Fukumori Y. 2006. Gadolinium diethylene triaminopentaacetic acid-loaded chitosan microspheres for gadolinium neutron-capture therapy. *Carbohydr Res* 341 (17):2835-2841.
- Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv Drug Deliv Rev* 55:3-29.

- Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. 1994. Disruption of the mouse *mdr1a* P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell* 77:491-502.
- Schwick HG, Heide K. 1969. Immunochemistry and immunology of collagen and gelatin. *Bibl Haematol* 33:111-125.
- Seelig A, Gottschlich R, Devant RM. 1994. A method to determine the ability of drugs to diffuse through the blood-brain barrier. *Proc Natl Acad Sci USA* 91:68-72.
- Sharom FJ. 1997. The P-glycoprotein efflux pump: how does it transport drugs? *J Membr Biol* 160:161-175.
- Silverstein RM, Webster FX. 1998. Spectroscopic identification of organic compounds. Sixth Edition, New York: John Wiley & Sons, 71-143.
- Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. 1998. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. *Proc Natl Acad Sci USA* 95:7024-7029.
- Sullivan PF, Kendler KS, Neale MC. 2003. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry* 60 (12):1187-1192.
- Terasaki T, Hosoya K. 1999. The blood-brain barrier efflux transporters as a detoxifying system for the brain. *Adv Drug Deliv Rev* 36:195-209.

- Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. 1999. *Adv Drug Deliv Rev* 36:277-290.
- Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res* 41:1967-1972.
- Van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA 2005. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. *Epilepsia* 46 (10):1569-1580.
- Van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA 2006. Inhibition of the multidrug transporter Pglycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. *Epilepsia* 47:672-680.
- Van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, Wadman WJ, Gorter JA 2007. Region-specific overexpression of Pglycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. *J Pharmacol Exp Ther* 322 (1):141-147.
- Varma NP, Sylaja PN, George L, Sarma PS, Radhakrishnan K. 2007. Employment concerns of people with epilepsy in Kerala, south India. *Epilepsy Behav* 10(2):250-254.

- Walker MC, Alavijeh MS, Shorvon SD, Patsalos PN 1996. Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex, *Epilepsia* 37(5):421-427.
- Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN 2000. Comparison of serum, cerebrospinal Fluid and brain extracellular Fluid pharmacokinetics of lamotrigine. *Br J Pharmacol* 130:242-248.
- Walton NY, Jaing Q, Hyun B, Treiman DM. 1996. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. *Epilepsy Res* 24(1):19-28.
- Walton NY, Treiman DM. 1990. Efficacy of AOC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. *Epilepsy Res* 5(2): 165-168.
- Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC 2012. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. *AAPS J* 14(3):543-553.
- Wu D, Pardridge WM. 1999. Blood-brain barrier transport of reduced folic acid. *Pharm Res* 16(3):415-419.
- Wu D, Pardridge WM. 1999. Neuroprotection with noninvasive neurotrophin delivery to the brain. *Proc Natl Acad Sci USA* 96:254-259.
- Yende SR, Harle UN, Bore VV, Bajaj AO, Shroff KK, Vetal YD. 2009. Reversal of neurotoxicity induced cognitive impairment associated with phenytoin and Phenobarbital by acorus calamus in mice. *J Herb Med Toxicol* 3(1):111-115.

- Zhang Y, Thomas TP, Desai A, Zong H, Leroueil PR, Majoros IJ, Baker JR, Jr. 2010. Targeted dendrimeric anticancer prodrug: A methotrexate-folic acid-poly(amidoamine) conjugate and a novel, rapid, “one pot” synthetic approach. *Bioconjug Chem* 21:489-495.
- Zhang Z, Roman G. 1993. Worldwide occurrence of Parkinson's disease: an updated review. *Neuroepidemiology* 12:195-208.
- Zillies JC, Zwioerek K, Hoffmann F, Vollmar A, Anchordoquy TJ, Winter G, Coester C. 2008. Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles. *Eur J Pharm Biopharm* 70(2):514-521.
- Zwioerek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C. 2008. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. *Pharm Res* 25(3):551-562.